Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Peginesatide in patients with anemia undergoing hemodialysis.

Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duliege AM, Besarab A; EMERALD Study Groups.

N Engl J Med. 2013 Jan 24;368(4):307-19. doi: 10.1056/NEJMoa1203165.

2.

Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.

Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM, Fishbane S; PEARL Study Groups.

N Engl J Med. 2013 Jan 24;368(4):320-32. doi: 10.1056/NEJMoa1203166.

3.

Correction of anemia with epoetin alfa in chronic kidney disease.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators.

N Engl J Med. 2006 Nov 16;355(20):2085-98.

4.

Relative safety of peginesatide and epoetin alfa.

Weinhandl ED, Gilbertson DT, Collins AJ, Foley RN.

Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1003-11. doi: 10.1002/pds.3655. Epub 2014 Jun 6.

PMID:
24905967
5.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators.

N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.

6.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. Epub 2007 May 23.

7.

Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators.

N Engl J Med. 2006 Nov 16;355(20):2071-84.

8.

An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.

Besarab A, Zeig SN, Martin ER, Pergola PE, Whittier FC, Zabaneh RI, Schiller B, Mayo M, Francisco CA, Polu KR, Duliege AM.

BMC Nephrol. 2012 Aug 30;13:95. doi: 10.1186/1471-2369-13-95.

9.

Peginesatide for the treatment of renal disease-induced anemia.

Schmid H.

Expert Opin Pharmacother. 2013 May;14(7):937-48. doi: 10.1517/14656566.2013.780695. Epub 2013 Mar 18. Review.

PMID:
23506424
10.

Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis.

Zabaneh R, Roger SD, El-Shahawy M, Roppolo M, Runyan G, O'Neil J, Qiu P.

Perit Dial Int. 2015 Jul-Aug;35(4):481-9. doi: 10.3747/pdi.2012.00224. Epub 2014 Mar 1.

PMID:
24584613
11.

The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Ishigami J, Onishi T, Shikuma S, Akita W, Mori Y, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y.

Clin Exp Nephrol. 2013 Feb;17(1):106-14. doi: 10.1007/s10157-012-0659-6. Epub 2012 Jul 3.

PMID:
22752396
12.
13.

[Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].

Jelić I, Lovcić V, Kurtović I, Josipović M, Havranek Z, Kostić L, Racki S.

Acta Med Croatica. 2012 Jul;66(3):157-64. Croatian.

PMID:
23441529
14.

Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa.

Fishbane S, Roger SD, Martin E, Runyan G, O'Neil J, Qiu P, Locatelli F.

Clin J Am Soc Nephrol. 2013 Apr;8(4):538-45. doi: 10.2215/CJN.03440412. Epub 2012 Dec 14.

15.
16.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
17.

Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.

Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ-Study Group.

Clin Nephrol. 2009 Nov;72(5):380-90.

PMID:
19863881
18.

Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise.

Hermanson T, Bennett CL, Macdougall IC.

Expert Opin Drug Saf. 2016 Oct;15(10):1421-6. doi: 10.1080/14740338.2016.1218467. Epub 2016 Aug 23. Review.

PMID:
27551882
19.

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.

Am J Kidney Dis. 2013 Jan;61(1):44-56. doi: 10.1053/j.ajkd.2012.07.014. Epub 2012 Aug 22.

20.

Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.

Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.

Am J Kidney Dis. 2002 Jul;40(1):110-8.

PMID:
12087568

Supplemental Content

Support Center